Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and week squamous cell carcinoma: Comparison of the circulating and tissue immunoreactive protein

Clinical Cancer Research

Volumn 11, Issue 9, 2005, Pages 3257-3264

  Ruokolainen, Henni ^a   Pääkkö, Paavo ^a   Turpeenniemi Hujanen, Taina ^a,b  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 18244390735     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2277     Document Type: Article

References (49)

1. Sanderson RJ, Ironside JA. Squamous cell carcinomas of the head and neck. Br Med J 2002;325:822-7.
2. Vokes EE, Weichselbaum RR, Lippman SM, Ki Hong W. Head and neck cancer. N Engl J Med 1993;328: 184-94.
3. Pivot X, Niyikiza C, Poissonnet G, et al. Clinical prognostic factors for patients with recurrent head and neck cancer: implications for randomized trials. Oncology 2001;61:197-204.
4. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
5. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18: 1135-49.
6. Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 1996;7:147-54.
7. Stetler-Stevenson WG, Yu AE. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 2001;11: 143-52.
8. Stetler-Stevenson WG. The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Surg Oncol Clin N Am 2001;10:383-92.
9. Väisänen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 1998;186:51-8.
10. Talvensaari-Mattila A, Pääkkö P, Höyhtyä M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 1998; 83:1153-62.
11. Sienel W, Hellers J, Morresi-Hauf A, et al. Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 2003;103: 647-51.
12. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 2001;7:3113-9.
13. Laack E, Köhler A, Kugler C, et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002;13:1550-7.
14. Ylisirniö S, Höyhtyä M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases-2, -9 and tissue inhibitors of metalloproteinases-1, -2 in lung cancer: TIMP-1 as a prognostic marker. Anticancer Res 2000; 20:1311-6.
15. Ranuncolo SM, Armanasco E, Cresta C, Bal De Kier Joffe E, Puricelli L. Plasma MMP-9 (92 kDa-MMP-9) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 2003;106:745-51.
16. Endo K, Maehara Y, Baba H, et al. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Anticancer Res 1997;17:2253-8.
17. Leppä S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res 2004;10:1057-63.
18. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992;298:29-32.
19. Denhardt DT, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM. Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther 1993;59:329-41.
20. Gomez DE, Alonso DF, Yoshiji H, Thorgeisson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions: Eur J Cell Biol 1997; 74:111-22.
21. Eccles SA, Box GM, Court WJ, et al. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor Batimastat (BB-94). Cancer Res 1996;56:2815-22.
22. Kossakowska AE, Urbanski SJ, Watson A, Hayden LJ, Edwards DR. Patterns of expression of metalloproteinases and their inhibitors in human malignant lymphomas. Oncol Res 1993;5:19-28.
23. Stevenson W, Brunner N. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 2000;6:4292-9.
24. Yoshikawa T, Tsuburaya A, Kobayashi O, et al. Intratumoral concentrations of tissue inhibitor of matrix metalloproteinase 1 in patients with gastric carcinoma a new biomarker for invasion and its impact in survival. Cancer 2001;91:1739-44.
25. Charous SJ, Stricklin GP, Nanney LB, Netterville JL, Burkey BB. Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in head and neck squamous cell carcinoma. Ann Otol Rhinol Laryngol 1997;106:271-8.
26. Kawamata H, Uchida D, Hamano H, et al. Active-MMP2 in cancer cell nests of oral cancer patients: correlation with lymph node metastasis. Int J Oncol 1998; 13:699-704.
27. Thomas GT, Lewis MP, Speight PM. Matrix metalloproteinase and oral cancer. Oral Oncol 1999;35: 227-33.
28. Kurahara S, Shinohara M, Ikebe T, et al. Expression of MMPs, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck 1999;21:627-38.
29. Miyajima Y, Nakano R, Morimatsu M. Analysis of expression of matrix metalloproteinases-2 and -9 in hypopharyngeal squamous cell carcinoma by in situ hybridization. Ann Otol Rhinol Laryngol 1995;104: 678-84.
30. Ruokolainen H, Pääkkö P, Turpeenniemi-Hujanen T. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clin Cancer Res 2004;10:3110-6.
31. International Union Against Cancer. TNM classification of malignant tumors. Geneva, Switzerland: Wiley-Liss; 1997. p.7-49.
32. Shanmugaratnam K: In collaboration with Sobin LH and Pathologists in 8 countries. Histological typing of tumours of the upper respiratory tract and ear. 2nd ed. World Health Organization international histological classification of tumours. Berlin: Springer-Verlag; 1991. p. 7-49.
33. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-81.
34. Manenti L, Paganoni P, Floriani I, et al. Expression levels of vascular endothelial growth factor, matrix metalloproteinases-2 and -9 and tissue inhibitor of metalloproteinases-1 and -2 in plasma of patients with ovarian carcinoma. Eur J Cancer 2003;39:1948-56.
35. Miyata Y, Kanda S, Nomata K, Hayashida Y, Kanetake H. Expression of metalloproteinase-2, metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: Correlation with tumor stage and survival. Urology 2004; 63:602-8.
36. Holten-Andersen M, Christensen IJ, et al. Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival: a validation study. Eur J Cancer 2004;40:64-72.
37. Kuvaja P, Talvensaari-Mattila A, Pääkkö P, Turpeeniemi-Hujanen T. The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1) but not for TIMP-2: protein is associated with a favourable prognosis in aggressive breast carcinoma. Oncology. In press.
38. Aljada IS, Ramnath N, Donohue K, et al. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J Clin Oncol 2004;22: 3218-29.
39. Yukawa N, Yoshikawa T, Akaike M, et al. Plasma concentration of tissue inhibitor of matrix metalloproteinase1 in patients with colorectal carcinoma. Br J Surg 2001;88:1596-601.
40. McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgins N, Duffy MJ. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999;84:44-8.
41. Talvensaari-Mattila A, Turpeenniemi-Hujanen T. High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma. Breast Cancer Res Treat 2005;89:29-34.
42. O-charoenrat P, Rhys-Evans PH, Eccles SA. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2001;127:813-20.
43. Kuropkat C, Plehn S, Herz U, Dunne AA, Renz H, Werner JA. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer. Anticancer Res 2002;22:2221-8.
44. Ikebe T, Shinohara M, Takeuchi H, et al. Gelatinolytic activity of matrix metalloproteinase in tumor tissue correlates with the invasiveness of oral cancer. Clin Exp Metastasis 1999;17:315-23.
45. Yoshikawa T, Saitoh M, Tsuburaya A. Tissue inhibitor of matrix metalloproteinase-1 in the plasma of patients with gastric carcinoma. Cancer 1999;86:1929-35.
46. De Angelis T, Noe A, Chatterjee M, Mulholland J. Stromelysin-1 activation correlates with invasiveness in squamous cell carcinoma. J Invest Dermatol 2002; 118:759-66.
47. Ikenaka Y, Yoshiji H, Kuriyama S, et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model. Int J Cancer 2003;105:340-6.
48. Kruger A, Fata JE, Khokha R. Altered tumour growth and metastasis of a T-cell lymphoma in TIMP-1 transgenic mice. Blood 1997;90:1993-2000.
49. Nakopoulou L, Katsarou S, Giannopoulou I, et al. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 2002;197:307-13.